Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 10/20 | 0.69 |
| ▸ | WDR77 | Q9BQA1 | 10/20 | 0.69 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27002313 | 0.88 | PRMT5 (0.52) | PRMT5WDR77GSK3AGSK3B | |
| SCHEMBL27002412 | 0.87 | PRMT5 (0.73) | PRMT5WDR77PARP1AAK1GSK3A | |
| SCHEMBL23087489 | 0.82 | PRMT5 (1.00) | PRMT5WDR77PARP1AAK1GSK3A | |
| SCHEMBL27385996 | 0.82 | PRMT5 (0.48) | PRMT5WDR77PARP1KDM4ELMNA | |
| SCHEMBL27002583 | 0.73 | PRMT5 (0.53) | PRMT5WDR77PARP1AAK1GSK3A | |
| SCHEMBL24094179 | 0.73 | PRMT5 (0.55) | PRMT5WDR77AAK1LMNA | |
| SCHEMBL23589994 | 0.71 | PRMT5 (0.52) | PRMT5WDR77AAK1KDM4E | |
| SCHEMBL29735249 | 0.71 | PRMT5 (0.77) | PRMT5WDR77PARP1CYP1A2 | |
| SCHEMBL3417194 | 0.70 | PRMT5 (0.49) | PRMT5WDR77AAK1GSK3AGSK3B | |
| SCHEMBL31376006 | 0.70 | PRMT5 (0.51) | PRMT5WDR77PARP1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | MIRATI THERAPEUTICS INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | MIRATI THERAPEUTICS INC (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4304720-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022192745-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT1, PRMT5, PRMT6 | PRMT5 2/4885WDR77 393/4885PARP1 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.